IQ Capital — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
IMU Biosciences uses a multi-omic platform to measure over 100 million immune data points from a single blood sample, resolving 2,500 immune cell subsets to build a large-scale immune dataset.
AI & Machine LearningBiotechHealthtechLondon, GB
Thomas Hayday PhD(Co-founder & Chief Research Officer)Adam Laing PhD(Co-founder & Chief Scientific Officer)Mario Cantero MBA(Co-founder & Chief Operating Officer)Adam Laing(Founder)inJohn Baker PhD(Chief Executive Officer)
Co-investorsExpaMolten Ventures
Turbine provides financing that lets venture capital firms and their limited partners borrow against fund positions and carried interest instead of selling them, giving GPs and LPs access to liquidity while retaining ownership.
Fintech
Co-investorsAlpha EdisonTTV CapitalB Capital GroupB4 CapitalEvolution VenturesTemerity Capital Partners+5 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.